From my knowledge so far only IMU's CF33 Oncolytic Virus ( OV ) , now in Ph1 and its B-cell vaccines HER-Vaxx ( complete Ph 2 ) and PD1-Vaxx ( in Ph1 ) have triggered the immune system response + memory effect.
If IVX gets on with the job then a few major milestones have to be achieved to get to PH 1 human trials. Peer reviews, safety profil ( IND approval ) and ethical approvals by the trial sides. Could take up to 2 years but if management is experienced or works together with experienced people then it could start earlier.
But I expect this anns to make big waves in the oncology sector.
GLTA
IVX Price at posting:
2.7¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)